English
Русский
O'zbek
ЗНАЧИМОСТЬ ПОКАЗАТЕЛЕЙ АНТИКОАГУ ЛЯНТНОЙ СИСТЕМЫ В ДИАГНОСТИКЕ ТРОМ БОЗОВ У БОЛЬНЫХ С КОВИД-19
Maqola haqida umumiy ma'lumotlar
Laboratory methods are a very important part of the examination of patients with thrombotic diseases, often putting the last stop in determining the diagnosis, and in some cases even determining this diagnosis. The presented review of thrombotic diseases and conditions, as well as laboratory meth ods for their diagnosis, allows us to differentiate these conditions at the laboratory stage of the exami nation and select the correct specific therapy, primarily antithrombotic. Antithrombin III (AT III) is a physiological anticoagulant, an inhibitor of plasma coagulation factors, and a plasma cofactor of heparin. It has the main inhibitory (anticoagulant) effect on the processes of blood coagulation. Deficiency of AT III in plasma is a serious risk factor for the development of thrombosis. Conversely, an increase in the level of ATIII leads to the risk of hemorrhagic complications. The article is a review of the literature on the diagnosis of hemostasis specifically of the antifibrinolytic system - Antithrombin -III, coagulopathy and venous thromboembolic complications associated with COVID-19.
1. Cuker A., Tseng EK., Nieuwlaat R. et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv (2021) 5 (3): 872–888.
2. Shamsutdsinova M.I, Hasanov A.M, Alimova H.P, Sobitkhodjaeva S.U, Musaeva K.B, Nu ralieva G.S, Giyasova M.G . Journal of Hunan University Natural Sciences. «Assessment of the influ ence of anticoagulant therapy on covid-19 course and outcome»
3. Wang Y., Lu X., Chen H., Chen T., Su N., Huang F. et al. ClinicalCourse and Outcomes of 344 Intensive Care Patients with.COVID-19. Am J Respir Crit Care Med. 2020;201(11):1430–1434.
4. World Health Orginization. WHO Coronavirus Disease (COVID-19)Dashboard. 2020 [cited 2020 02.06]. Available at: https:// covid19.who.int/.
5. Di Micco P, Russo V, Carannante N, Imparato M, Rodolfi S, Cardillo G, et al. Clotting factors in COVID-19: epidemiological association andprognostic values in different clinical presentations in an Italian Cohort.J Clin Med. (2020) 9:1371.
6. Fontana P, Casini A, Robert-Ebadi H, Glauser F, Righini M, Blondon M. Venous thromboem bolism in COVID-19: systematic review of reported risks and current guidelines. Swiss Med Wkly. (2020) 150:w20301.
7. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagu lation. Lancet Respir Med. (2020) 8:e46–7.
8. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. ESC Scien tific Document Group developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. (2020) 41:543–603. 9. M. Levi, M. Scully, How I treat disseminated intravascular coagulation. Blood. (2018) 131:845 -54.
10. M. Levi, M. Scully, How I treat disseminated intravascular coagulation. Blood. (2018) 131:845 McCloskey B, Heymann DL. SARS to novel coronavirus: old lessons and new lessons. Epidemi olInfect. (2020) 148:e22.
11. C A R J I S Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest. (2020) 158:1143–63.
12. Russo V, Bottino R, Carbone A, Rago A, Papa AA, Golino P, et al. COVID-19 and heart: from clinical features to pharmacological implications.J Clin Med. (2020) 9:E1944.
13. Russo V, Rago A, Carbone A, Bottino R, Ammendola E, Della Cioppa N, et al. Atrial fibrillation in COVID-19: from epidemiological association to pharmacological implications. J Cardiovasc Phar macol. (2020) 76:138–45.
14. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with de creased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. (2020) 18:1094– 9.
15. Mega JL, Braunwald E, Wiviott SD, et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366(01):9–19.
16. EikelboomJW, Connolly SJ, Bosch J, et al; COMPASS Investigators. Rivaroxaban with or with out aspirin in stable cardiovascular disease. N Engl J Med 2017;377(14):1319–1330.
17. Cohen AT, Spiro TE, Büller HR, et al; MAGELLAN Investigators. Rivaroxaban for thrombo prophylaxis in acutely ill medical patients. N Engl J Med 2013;368(06):513–523.
18. Spyropoulos AC, Ageno W, Albers GW, et al; MARINER Investigators. Rivaroxaban for throm boprophylaxis after hospitalization for medical illness. N Engl J Med 2018;379(12):1118–1127. 19. Cohen AT, Harrington RA, Goldhaber SZ, et al; APEX Investigators. Extended thromboprophy laxis with betrixaban in acutely ill medical patients. N Engl J Med 2016;375(06):534–544.
20. Временные методические рекомендации по профилактике, диагностике, лечению и реа билитации при коронавирусной инфекции (COVID-19), Версия 8, 2020. (03.09.2020).
21. Громов А.А., Кручинина М.В., Рабко А.В. Коронавирусная болезнь COVID-19: неисполь зованные возможности терапии. РМЖ. 2020, №9. С.2-6
, С. ., , Б. ., & , Ш. . (2026). ЗНАЧИМОСТЬ ПОКАЗАТЕЛЕЙ АНТИКОАГУ ЛЯНТНОЙ СИСТЕМЫ В ДИАГНОСТИКЕ ТРОМ БОЗОВ У БОЛЬНЫХ С КОВИД-19. ALFRAGANUS, 6(4), 69–73. https://doi.org/
, Сабитходжаева С.У., et al. “ЗНАЧИМОСТЬ ПОКАЗАТЕЛЕЙ АНТИКОАГУ ЛЯНТНОЙ СИСТЕМЫ В ДИАГНОСТИКЕ ТРОМ БОЗОВ У БОЛЬНЫХ С КОВИД-19.” Academic Research in Educational Sciences, vol. 4, no. 6, 2026, pp. 69–73, https://doi.org/.
, ., , ., and , . 2026. ЗНАЧИМОСТЬ ПОКАЗАТЕЛЕЙ АНТИКОАГУ ЛЯНТНОЙ СИСТЕМЫ В ДИАГНОСТИКЕ ТРОМ БОЗОВ У БОЛЬНЫХ С КОВИД-19. Academic Research in Educational Sciences. 4(6), pp.69–73.